Molecular Microbiology (Virology)
Institute of Medical Microbiology and Hygiene
University Regensburg


Funding: The Federal Ministry of Education and Research (BMBF)
Title: HI
V Vaccine Targeting via DNA Origami Nanoparticles to lymph nodes to promote Germinal Center formation

HIV has so far defied all attempts to develop an effective vaccine against it. Nine efficacy trials testing several vaccine candidates have been conducted in the last 25 years, with only one of them resulting in very modest, insufficient protection. One trial, PrEPVacc is still ongoing.

Yet, in the 40 years since HIV’s discovery, a lot has been learned about the virus and the reaction of the human immune system, as well as the means how HIV escapes the immune response.

Project partners:
Molecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg – Project co-ordinator,
Pharmaceutical Technology, University of Regensburg,
Technical University of Munich (TUM),
Helmholtz Zentrum München,
Tilibit nanosystems GmbH,
2bind GmbH

Further information:
HIVacToGC Project site